Bruno Giros - Curriculum Vitae#

  • 1983 - 1987 Enkephalin metabolism in the brain.
    During my thesis work, I completed the characterization of Aminopeptidase M (APM) involvement in the endogenous degradation of cerebral enkephalins
  • 1988 - 1991 Study of dopamine receptors
  • After a 6 month stay at Genentech Inc, I initiated Molecular Biology in the Jean-Charles Schwartz’s laboratory. Together with P. Sokoloff, we cloned two isoforms for the dopamine D2 receptor and characterized a novel dopamine receptor, the D3 receptor. The discovery of this novel dopamine receptor with high affinity for antipsychotics, was very provocative at this time, where everybody thought that only two dopamine receptors existed
  • 1992 - 1998 Miscellaneous.
    Gene characterization and knockout of the ß-Adrenergic Receptor Kinase-1. Involvement of the glycine receptor ß subunit in the neurological mutation spastic in mice. Molecular and functional characterization of the vesicular transporter for GABA and Glycine
  • 1991 Study of neuronal transporters
    Molecular cloning and characterization of the rat and human dopamine transporters. Structure-activity relationships studies. Molecular cloning of the Lysosomal amino-acids Transporter, the glycine Transporter, the creatine Transporter, orphan Transporters RxT-1 and -2 and Vesicular Glutamate Transporters. First knockout of a transporter for neurotransmitter, the dopamine transporter. The functional and behavioral study of KO mice gave rise to > 100 papers (the strain was widely distributed). Conditional KO of the Vesicular transporter VMAT2.
  • 1999 - 2008 Director of the INSERM U-513 laboratory “Neurobiology and Psychiatry”
  • 2009 - 2013 Director of the CNRS/INSERM laboratory "Pathophysiology of CNS Disorders"
  • 2008 Canada Research Chair "Neurobiology of Mental Disorders"

In addition to the above projects which are still ongoing:
  • Development and use of animal models to understand the mechanisms involved in the pathophysiology of psychiatric disorders, with focus on depression and schizophrenia.
  • Co-founder of Melkin Pharmaceuticals in 2015 (

Imprint Privacy policy « This page (revision-4) was last changed on Tuesday, 26. July 2022, 17:32 by System
  • operated by